Serum liver fatty acid binding protein shows good correlation with liver histology in NASH

Hepato-Gastroenterology

Volumn 60, Issue 125, 2013, Pages 1095-1100

  Özenirler, Seren ^a   Degertekin, Ceyla Konca ^a   Erkan, Gulbanu ^b   Elbeǧ, Şehri ^a   Tuncer, Candan ^a   Kandilci, Uǧur ^a   Akyol, Gülen ^a  

^a GAZI UNIVERSITY FACULTY OF MEDICINE   (Turkey)

^b UFUK UNIVERSITY   (Turkey)

Author keywords

Liver histology; Liver type fatty acid binding protein; Non alcoholic steatohepatitis

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; FATTY ACID BINDING PROTEIN; TRIACYLGLYCEROL;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY MASS; CONTROLLED STUDY; DISEASE SEVERITY; FATTY ACID METABOLISM; FATTY LIVER; FEMALE; HEPATITIS; HUMAN; HUMAN TISSUE; LIVER FIBROSIS; LIVER HISTOLOGY; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SCORING SYSTEM; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; FATTY ACID-BINDING PROTEINS; FATTY LIVER; FEMALE; HUMANS; LIVER; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX;

EID: 84885758585     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: 10.5754/hge11949     Document Type: Article

References (19)

1. Marchesini G, Bugianesi E, Forlani G, et al.: Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003; 37(4):917-923.
2. Browning JD, Szczepaniak LS, Dobbins R, et al.: Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004; 40(6):1387-1395.
3. Fracanzani AL, Valenti L, Bugianesi E, et al.: Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. Hepatology 2008; 48(3):792-798.
4. Pelsers MM, Morovat A, Alexander GJ, Hermens WT, Trull AK, Glatz JF: Liver fatty acid-binding protein as a sensitive serum marker of acute hepatocellular damage in liver transplant recipients. Clin Chem 2002; 48(11):2055-2057.
5. Bass NM, Barker ME, Manning JA, Jones AL, Ockner RK: Acinar heterogeneity of fatty acid binding protein expression in the livers of male, female and clofibrate-treated rats. Hepatology 1989; 9(1):12-21.
6. Pelsers MM, Namiot Z, Kisielewski W, et al.: Intestinal-type and liver-type fatty acid-binding protein in the intestine. Tissue distribution and clinical utility. Clin Biochem 2003; 36(7):529-535.
7. Lam KT, Borkan S, Claffey KP, Schwartz JH, Chobanian AV, Brecher P: Properties and differential regulation of two fatty acid binding proteins in the rat kidney. J Biol Chem 1988; 263(30):15762-15768.
8. Murphy EJ, Prows DR, Jefferson JR, Schroeder F: Liver fatty acid-binding protein expression in transfected fibroblasts stimulates fatty acid uptake and metabolism. Biochim Biophys Acta 1996;1301(3):191-198.
9. Newberry EP, Xie Y, Kennedy SM, Luo J, Davidson NO: Protection against Western diet-induced obesity and hepatic steatosis in liver fatty acid-binding protein knockout mice. Hepatology 2006; 44(5):1191-1205.
10. Newberry EP, Xie Y, Kennedy S, et al.: Decreased hepatic triglyceride accumulation and altered fatty acid uptake in mice with deletion of the liver fatty acid-binding protein gene. J Biol Chem 2003; 278(51):51664-51672.
11. Wolfrum C, Borrmann CM, Borchers T, Spener F: Fatty acids and hypolipidemic drugs regulate peroxisome proliferator-activated receptors alpha - and gamma-mediated gene expression via liver fatty acid binding protein: a signaling path to the nucleus. Proc Natl Acad Sci U S A 2001; 98(5):2323-2328.
12. Weickert MO, Loeffelholz CV, Roden M, et al.: A Thr94Ala mutation in human liver fatty acid-binding protein contributes to reduced hepatic glycogenolysis and blunted elevation of plasma glucose levels in lipid-exposed subjects. Am J Physiol Endocrinol Metab 2007; 293(4):E1078-1084.
13. American Diabetes Association: Diagnosis and classification of diabetes mellitus. Diabetes Care 2009; 32 Suppl 1:S62-67.
14. Kleiner DE, Brunt EM, Van Natta M, et al.: Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41(6):1313-1321.
15. Ockner RK, Manning JA, Kane JP: Fatty acid binding protein. Isolation from rat liver, characterization, and immunochemical quantification. J Biol Chem 1982; 257(13):7872-7878.
16. Makowski L, Brittingham KC, Reynolds JM, Suttles J, Hotamisligil GS: The fatty acid-binding protein, aP2, coordinates macrophage cholesterol trafficking and inflammatory activity. Macrophage expression of aP2 impacts peroxisome proliferator-activated receptor gamma and IkappaB kinase activities. J Biol Chem 2005; 280(13):12888-12895.
17. Hostetler HA, McIntosh AL, Atshaves BP, et al.: L-FABP directly interacts with PPARalpha in cultured primary hepatocytes. J Lipid Res 2009; 50(8):1663-1675.
18. Skrtic S, Carlsson L, Ljungberg A, et al.: Decreased expression of peroxisome proliferator-activated receptor alpha and liver fatty acid binding protein after partial hepatectomy of rats and mice. Liver Int 2005; 25(1):33-40.
19. Westerbacka J, Kolak M, Kiviluoto T, et al.: Genes involved in fatty acid partitioning and binding, lipolysis, monocyte/macrophage recruitment, and inflammation are overexpressed in the human fatty liver of insulin-resistant subjects. Diabetes 2007; 56(11):2759-2765.